A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of MDX-1106 in Subjects With Selected Advanced or Recurrent Malignancies

For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

- Subjects must have mCRPC,RCC, MEL, Non-small-cell lung cancer (NSCLC), or Colorectal
Cancer (CRC), that is advanced (non-resectable), or recurrent and for which no
alternative, curative standard exists

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

- Must have at least 1 measurable lesion

- Subjects with mCRPC and with only non-measurable bone lesions must have either
progression new lesions or have Prostate-specific antigen (PSA) progression within
the 6-week period before study administration

- At least 1 and up to 5 prior systemic therapies for advanced/recurrent disease

- Prior treated brain or meningeal metastases must be without Magnetic resonance
imaging (MRI) evidence of progression for at least 8 weeks and off immunosuppressive
doses of systemic steroids for at least 2 weeks before study drug administration

- Prior systemic radiation therapy must have been completed at least 4 weeks before
study drug administration. Prior focal radiotherapy completed at least 2 weeks prior
to study drug administration

- Immunosuppressive doses of systemic medications, such as steroids or absorbed topical
steroids must be discontinued at least 2 weeks before study drug administration

- Prior surgery that required general anesthesia must be completed at least 2 weeks
before study drug administration. Surgery requiring local/epidural anesthesia must be
completed at least 72 hours before study drug administration

Exclusion Criteria:

- History of severe hypersensitivity reactions to other Monoclonal antibody (mAb)s

- Subjects with any active autoimmune disease or a documented history of autoimmune
disease, or history of syndrome that required systemic steroids or immunosuppressive
medications, except for subjects with vitiligo or resolved childhood asthma/atopy

- Prior therapy with an anti-Programmed death-1 (PD-1), anti-PD-L1, anti-PDL-2, or
anti- Cytotoxic t-lymphocyte antigen-4 (CTLA-4) antibody (or any other antibody
targeting T cell co-stimulation pathways)

- Known history of Human Immunodeficiency Virus

- Active infection requiring therapy, positive tests for Hepatitis B surface antigen or
Hepatitis C ribonucleic acid (RNA)

- Underlying medical conditions that will make the administration of study drug
hazardous

- Concurrent medical condition requiring the use of immunosuppressive medications, or
immunosuppressive doses of systemic or absorbable topical corticosteroids

- Use of other investigational drugs (drugs not marketed for any indication) within 28
days or at least 5 half-lives (whichever is longer) before study drug administration